HCA Healthcare/$HCA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About HCA Healthcare
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the United States. As of December 2025, the firm owned and operated 190 hospitals and over 2,500 outpatient facillities across 19 states and a small foothold in the United Kingdom.
- Ticker
- $HCA
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 275,000
- Headquarters
- Nashville, United States
- Website
- www.hcahealthcare.com
HCA Healthcare Metrics
BasicAdvanced
$99B
15.66
$30.22
1.11
$3.06
0.66%
Price and volume
Market cap
$99B
Beta
1.11
52-week high
$556.52
52-week low
$353.99
Average daily volume
1.2M
Dividend rate
$3.06
Financial strength
Current ratio
0.82
Quick ratio
0.633
Long term debt to equity
-9.64
Total debt to equity
-11.399
Dividend payout ratio (TTM)
10.05%
Interest coverage (TTM)
5.10%
Profitability
EBITDA (TTM)
15,791
Gross margin (TTM)
42.76%
Net profit margin (TTM)
8.61%
Operating margin (TTM)
15.31%
Effective tax rate (TTM)
20.60%
Revenue per employee (TTM)
$290,000
Management effectiveness
Return on assets (TTM)
12.23%
Return on equity (TTM)
-230.81%
Valuation
Price to earnings (TTM)
15.656
Price to revenue (TTM)
1.331
Price to book
-12.73
Price to tangible book (TTM)
-5.33
Price to free cash flow (TTM)
17.536
Free cash flow yield (TTM)
5.70%
Free cash flow per share (TTM)
26.984
Dividend yield (TTM)
0.65%
Forward dividend yield
0.66%
Growth
Revenue change (TTM)
5.82%
Earnings per share change (TTM)
17.05%
3-year revenue growth (CAGR)
7.61%
10-year revenue growth (CAGR)
6.71%
3-year earnings per share growth (CAGR)
13.98%
10-year earnings per share growth (CAGR)
16.95%
3-year dividend per share growth (CAGR)
9.04%
What the Analysts think about HCA Healthcare
Analyst ratings (Buy, Hold, Sell) for HCA Healthcare stock.
Analyst projections of the future price of HCA Healthcare stock.
Bulls say / Bears say
HCA beat third-quarter earnings expectations, with adjusted EPS of $7.22 against a $6.66 consensus, and now expects full-year results in the upper half of its guidance range. (Reuters, HCA Healthcare)
Patient demand remains firm: same-facility equivalent admissions rose 3.0% and emergency-room visits increased 5.1% in the third quarter. HCA also reported improved cost results despite the difficult payer mix. (HCA Healthcare)
HCA is growing its outpatient network, with a target of 20 outpatient sites per hospital by 2030, up from more than 14 today. Continued clinic acquisitions and new facility plans could widen its reach in growing markets. (Becker's Hospital Review, HCA Florida Healthcare)
The shift towards uninsured patients remains costly: HCA estimated it reduced pre-tax income by about $400 million in the third quarter, while reported net income fell 3.9% year on year. (HCA Healthcare, Reuters)
Surgical activity is weakening even as overall admissions grow: same-facility inpatient surgeries fell 1.4% and outpatient surgeries fell 3.7% in the third quarter. Lower elective-care volumes could weigh on revenue and margins. (HCA Healthcare, Reuters)
Medicaid policy changes could add pressure to reimbursement, and analysts have flagged the expected roll-off of roughly $520 million in non-recurring Florida provider payments alongside new work requirements. That makes earnings more exposed to government funding decisions. (Investing.com, HCA Healthcare)
Data summarised monthly by Lightyear AI. Last updated on 27 Oct 2026.
HCA Healthcare Financial Performance
Revenues and expenses
HCA Healthcare Earnings Performance
Company profitability
Upcoming events
HCA Healthcare News
AllArticlesVideos
Funds containing HCA Healthcare
AllUSDEURGBP
Fund name | Fund size | $HCA weighting |
|---|---|---|
Invesco Health Care S&P US Select Sector£XLVP | $552M | 1.10% |
Invesco Health Care S&P US Select Sector$XLVS | $552M | 1.10% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 1.05% |
SPDR MSCI World Health Care$WHEA | $708M | 0.83% |
SPDR MSCI World Health Care£HEAW | $708M | 0.83% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.